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Abstract
Background: We previously showed that tumor-free peritoneum of patients with epithelial ovarian cancer
(EOC) exhibited enhanced expression of several inflammatory response genes compared to peritoneum of benign
disease. Here, we examined peritoneal inflammatory cell patterns to determine their concordance with selected
enhanced genes.
Methods: Expression patterns of selected inflammatory genes were mined from our previously published data
base. Bilateral pelvic peritoneal and subjacent stromal specimens were obtained from 20 women with EOC and
7 women with benign pelvic conditions. Sections were first stained by indirect immunoperoxidase and numbers
of monocytes/macrophages (MO/MA), T cells, B cells, and NK cells counted. Proportions of CD68+ cells and
CD3+ cells that coexpressed MO/MA differentiation factors (CD163, CCR1, CXCR8, VCAM1, and
phosphorylated cytosolic phospholipase A2 [pcPLA2]), which had demonstrated expression in EOC peritoneal
samples, were determined by multicolor immunofluorescence.
Results: MO/MA were present on both sides of the pelvic peritoneum in EOC patients, with infiltration of the
subjacent stroma and mesothelium. CD68+ MO/MA, the most commonly represented population, and CD3+ T
cells were present more often in EOC than in benign pelvic tumors. NK cells, B cells, and granulocytes were rare.
CXCL8 (IL-8) and the chemokine receptor CCR1 were coexpressed more frequently on MO/MA than on CD3+
cells contrasting with CD68+/CD163+ cells that coexpressed CXCL8 less often. An important activated enzyme
in the eicosanoid pathway, pcPLA2, was highly expressed on both CD68+ and CD163+ cells. The adherence
molecule Vascular Cell Adhesion Molecule-1 (VCAM1) was expressed on CD31+ endothelial cells and on a
proportion of CD68+ MO/MA but rarely on CD3+ cells.
Conclusion: The pelvic peritoneum in EOC exhibits a general pattern of chronic inflammation, represented
primarily by differentiated MO/MA, and distinct from that in benign conditions concordant with previous profiling
results.
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Background
Epithelial ovarian cancer (EOC) results in 5 year survival
rates of only 25–30% for patients with stage III and IV dis-
ease [1], contrasting with the 90% survival rates of
patients with stage I disease, where notably peritoneal and
serosal disease is absent. It is perhaps a paradox that the
peritoneum which is organized to protect the integrity of
intraabdominal organs by facilitating infiltration of
inflammatory cells to sites of injury and infection, might
also serve to facilitate the promotion of tumor growth and
spread.
As EOC advances and penetrates the capsular layer of the
ovary, it also carries the potential to expose the peritoneal
surface to tumor-cell secreted products. The peritoneum
and its extension, the intestinal serosa, include a vast sur-
face area for transit of inflammatory cells into the abdom-
inal cavity. Its surface mesothelium and submesothelial
stroma and structure pose no substantial barriers to
inflammatory modulatory cytokines, chemokines and
other molecules produced by the tumor or its metastasis,
at least to a depth of approximately 1 mm [2]. The stroma
consists of a collagen-based matrix, blood vessels, lym-
phatics, nerve fibers, and rare hematogenous cells [3,4].
Surgery for EOC often reveals changes in the non-tumor-
bearing peritoneum such as thickening or edema,
enhanced vascular patterns, and soft or firm adhesions
[5]. The peritoneum and intestinal serosa may have a
florid appearance similar to that found in peritonitis.
Despite this evidence of inflammation, the inflammatory
process in the peritoneum of patients with EOC has not
been adequately described or characterized.
Using a previously validated cDNA microarray platform
consisting of 17,500 clones enriched with inflammatory
and immunologically relevant genes [6-8], we previously
showed that the gene profiles of the pelvic peritoneum in
patients with EOC exhibited a pattern consistent with the
presence of MO/MA differentiation, activation, and cell
survival and that the pattern was different from that of the
peritoneum of patients without cancer or that of the
tumor itself [9]. Categorizing genes on the basis of anno-
tated gene function led to our observing that genes associ-
ated with inflammation were overexpressed in non-tumor
bearing peritoneum of patients with ovarian cancer as
compared with the peritoneum of patients with benign
ovarian tumors.
The purpose of the study reported here was to describe the
global pattern of the main inflammatory cell populations
in the peritoneum and stroma and to determine whether
the magnitude of expression of a limited group of inflam-
matory genes could be confirmed at the cellular pro-
teomic level in peritoneal tissue and ascites cells.
Methods
Peritoneal and subjacent stromal biopsy specimens were
obtained from 20 patients with EOC and from 7 patients
with benign ovarian or other pelvic tumors who under-
went surgery at M. D. Anderson Cancer Center according
to a protocol approved by the appropriate institutional
review board. Demographic characteristics of those
patients are shown in Table 1. Biopsy samples were
obtained from the peritoneum and from the submesothe-
lial stroma on both sides of the pelvis, approximately 2
cm from the nearest visible tumor deposits, as quickly as
possible after the abdominal cavity was accessed. Perito-
neal biopsy samples were obtained carefully without prior
manipulation of the chosen biopsy sites to minimize arti-
fact induced variability. As controls, specimens were
obtained from similar peritoneal sites in consenting sub-
jects who were undergoing pelvic abdominal surgery but
who did not have a diagnosis of cancer. The combined
thickness of the peritoneal and separately obtained deeper
stromal biopsy specimens was estimated at 1–2 millime-
ters. A technician was present in the operating room to
receive and process all biopsy specimens. All specimens
were bisected. One portion, for histopathologic, immu-
nohistochemical, and immunofluorescence costaining,
was collected and transported to the lab on ice where it
was snap-frozen in Polyfreeze Tissue Freezing Medium
(Polysciences, Warrington, PA). Another portion, to be
used for microarray, was placed in a sterile tube contain-
ing 5% dextrose 0.2% sodium chloride solution and
transported on ice to the laboratory. The tissue was
removed from the saline solution and snap-frozen in a
vial with RNAlater (Ambion, Austin, TX) to minimize
RNA metabolism and degradation. Subsequently, perito-
neal tissue was also obtained from several additional
patients for eicosanoid studies. This tissue was placed dry
into a sterile tube and snap-frozen in liquid nitrogen in
the operating room. All tissues were stored at -80°C.
Benign cases included: ovarian fibrothecoma (3), serous
cystoadenoma or cystoadenofibroma (3), and ovarian
papillary proliferation (1). A gynecologic pathologist
(M.D.) reviewed all hematoxylin-and-eosin (H&E) -
stained sections from specimens used in this study. Peri-
toneal specimens showing microscopic tumor involve-
ment were not included in the studies described here.
Immunohistochemical staining of peritoneal biopsy tissues
Indirect immunoperoxidase (IIP) staining
To determine the proportions of infiltrating mononuclear
leukocyte populations in the peritoneal stroma, cryopre-
served peritoneal biopsy specimens were cut and stained,
using an avidin-biotin immunoperoxidase method
[10,11]. IIP staining is generally considered more sensitive
and specific than H&E for staining and identifying mono-
nuclear leukocyte populations in cryopreserved tissue.
Briefly, 6-μm sections of cryopreserved peritoneal tissuesJournal of Translational Medicine 2006, 4:30 http://www.translational-medicine.com/content/4/1/30
Page 3 of 11
(page number not for citation purposes)
were immediately fixed with acetone for 10 minutes, air-
dried for 30 minutes, and then kept at 20°C overnight.
Sections were then air-dried for another 30 minutes at
room temperature and endogenous peroxidase activity
was blocked by incubation in 0.3% H2O2 in PBS for 15
minutes. Sections were then washed three times in PBS,
and nonspecific reactions were blocked with 2% normal
horse serum for 30 minutes. Sections were then incubated
for 2 hours at room temperature with the primary anti-
bodies as follows. For the immunohistochemical analy-
ses, primary antibodies were: Mouse anti-human CD45
leukocyte common antigen [LCA] clones 2B11 + PD7/26,
catalog no. M0701, Mo IgG1, 1/400 (DakoCytomation,
Carpinteria, CA); mouse anti-human CD3 clone T3-4B5,
catalog no. M0756, Mo IgG1, 1/225 (DakoCytomation);
mouse monoclonal antibody KP1 to CD68, catalog no.
ab955, Mo IgG1, 1/2000 (Abcam, Cambridge, MA);
mouse anti-SCLC (CD56, N-CAM) clone 123C3. Mo
IgG1, 1/50 (Zymed Labs, San Francisco, CA); and mouse
anti-human CD20 clone B-LyI, catalog no. M0774, Mo
IgG1 kappa 1/700 (DakoCytomation). Secondary anti-
bodies used were: biotinylated horse anti-mouse IgG
(1:200) (Vector Laboratories, Burlingame, CA); Universal
LSAB kit/HRP Rabbit/Mouse, catalog no. K0675 (Dako-
Cytomation), and appropriate isotype controls. Optimal
conditions for staining with each antibody were deter-
mined by using appropriate test tissues. After being
washed with PBS three times, sections were incubated
with the appropriate secondary antibody for 1 hour at
room temperature. Sections were then washed again with
PBS and incubated with avidin-biotin peroxidase conju-
gate (ABC Kit, Vector Laboratories, catalog no. PK6102) at
a dilution of 1:100 for 30 minutes at room temperature,
after which AEC substrate (Vector Laboratories, catalog
no. SK-4200) was added for 10 minutes. Sections were
washed with tap water, counterstained with Vector hema-
toxylin (Vector Laboratories) for 1 minute, and mounted
with permanent aqueous mounting medium (Biomeda,
Foster City, CA, catalog no. M03) [10].
Coded slides for indirect immunoperoxidase staining
were counted in nine areas per tissue section by random
field selection, and the number of cells was averaged per
0.08 mm2. Distributions and ratios of MO/MA and T cells
were determined by quantitative immunochemical analy-
sis with a Leica DM LB (Leica, Germany) image analyzer
equipped with Image Pro Plus software (Media Cybernet-
ics, Silver Springs, MD) [9]. The Image ProPlus software
program evaluates random counting of positive cells by
using a grid mask in the process menu, and artifacts are
removed by using the delete option.
Multi antibody immunofluorescence costaining and confocal 
microscopy of peritoneal biopsy specimens
In situ cell populations or subsets were examined by mul-
ticolor immunofluorescence costaining to detect surface
receptors and certain cytoplasmic proteins that had been
identified in our previous transcriptome studies [9,12].
For the experiments described here, CCR1, CXCL8 (IL-8),
CD163, and VCAM1 were included for costaining mono-
Table 1: Clinical characteristics of the 20 chemo-naive patients with epithelial ovarian cancer
Characteristics N (%)
Mean Age, years (range)
Patients with malignant disease (n = 20) 60 (36 – 79)
Patients with benign ovarian disease (n = 7) 64 (47 – 83)
EOC Histology
Serous 10 (50%)
Mucinous 2 (10%)
Endometrioid 2 (10%)
Clear cell 1 (5%)
Mixed 5(25%)
Disease Stage
I – II 2 (10%)
III – IV 18 (90%)
Tumor Grade
I 2 (10%)
II 2 (10%)
III 16 (80%)
Surgical Debulking
Optimal 11 (55%)
Suboptimal 9 (45%)Journal of Translational Medicine 2006, 4:30 http://www.translational-medicine.com/content/4/1/30
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nuclear leukocytes that expressed CD68+ or CD3+. In
some experiments, MO/MA and the CD163+ subset were
costained with phosphorylated cytosolic phospholipase 2
(cPLA2), which together with sPLA2 (Group 2a) was over-
expressed in peritoneal samples from EOC patients.
Freshly cut tissues (6 μm) were fixed in 4% paraformalde-
hyde for 20 minutes at room temperature, after which sec-
tions were washed in PBS, permeabilized with 0.5%
Triton 100×, blocked with 5% normal goat serum, and
incubated with primary antibodies overnight at 4°C.
IIF triple costaining
A sequential staining technique was used for this method
as follows: 3 hours incubation with the first primary anti-
body (red) at RT, overnight incubation with the second
primary antibody (blue) at 4°C, and 3 hours incubation
with the third primary antibody at RT. Secondary antibod-
ies were incubated with the sections for 1 hour after the
incubations with the primary antibodies were complete.
Nonspecific binding was blocked by adding 5% normal
goat serum for 1 hour. The primary antibodies used were:
mouse anti-human CD3 clone T3-4B5, Mo IgG1 kappa,
1:225 dilution, catalog no. M0756 (DakoCytomation);
polyclonal rabbit anti-human CD3, 1:100, catalog no.
A0452 (DakoCytomation); mouse anti-human CD68,
Mo IgG2a, 1:30, catalog no. MCA1815 (Serotec, Raleigh,
NC); mouse monoclonal antibody KP1 to CD68, Mo
IgG1 kappa, 1:1500, catalog no. ab955 (Abcam); mouse
anti-human CD163, Mo IgG1, 1:100, catalog no.
MCA1853 (Serotec); mouse anti-humanVCAM1 clone
1.4C3, Mo IgG1 kappa, 1:50, catalog no. M7106 (Dako-
Cytomation); mouse anti-human CCR1, Mo IgG2B,
1:100, catalog no. MAB145 (R&D Systems, Minneapolis,
MN); mouse anti-human CD14, Mo IgG2a kappa, catalog
no. M0825 (DakoCytomation); polyclonal rabbit anti-
human IL-8, 1:5, catalog no. AHC0881 (Biosource,
Camarillo, CA); phospho-cPLA2 (Ser 505) antibody (rab-
bit) #2831, 1:50 (Cell Signaling Technology, Danvers,
MA); mouse anti-human CD31 (PECAM-1, Platelet gpIIa
Molecule), catalog no. C2383-02, Mo IgG2b, 1:100
(United States Biological, Swampscott, MA); and mouse
anti-human cytokeratin clone AE1/AE3, Mo IgG1 kappa,
1:50, catalog no. M3515 (DakoCytomation). The second-
ary antibodies used depended on the isotype of the pri-
mary antibodies, and included Cy2-conjugated (green)
AffiniPure goat anti-mouse IgG, Fcγ subclass 1-specific,
catalog no. 115–225-205; Cy3-conjugated (red) Affin-
iPure goat anti-rabbit IgG (H+L), catalog no. 111–165-
144; Cy5-conjugated (blue) AffiniPure goat anti-mouse
IgG, Fcγ subclass 2b-specific, catalog no. 115–175–207;
Cy5-conjugated (blue) AffiniPure goat anti-mouse IgG,
Fcγ subclass 2a-specific, catalog no. 115–175–206; Cy3-
conjugated (red) AffiniPure goat anti-mouse IgG, Fcγ sub-
class 2a-specific (minimal cross-reaction with bovine, and
rabbit serum proteins), catalog no. 115–165–206 (all
from Jackson ImmunoResearch Laboratories, West Grove,
PA). Negative controls employed secondary antibodies
alone.
Tissue sections were mounted with Slow-Fade Gold Anti-
Fade reagent (catalog no. S36936, Molecular Probes) and
viewed with a Olympus FV500 laser scanning confocal
microscope; images were captured at 400× and 600× mag-
nification by Fluoview software Version 4.3.
Statistics
Wilcoxon tests were used to compare the distribution of
markers between malignant and benign samples. Paired t-
tests were used to compare inflammatory cell numbers
from each side of the pelvis and between the superficial
and deeper stroma.
Results and discussion
We first examined our data base of more than 50 inflam-
mation-linked genes that have been shown to be
expressed differently in malignant and benign perito-
neum [9]. The genes in Figure 1 were mined from a data-
base that supported our earlier report on the peritoneal
transcriptome [9]. Gene expression levels were generated
by centering followed by cluster analysis and displayed as
dendrograms (trees) [13]. Here we show expression of
several of these genes that encode for the following mole-
cules: CXCL8, a contributor to tumor angiogenesis and
leukocyte chemotaxis, CD163 the scavenger molecule
associated with MA differentiation, CCR1, a chemokine
receptor expressed on different leukocytes, including MA
and that binds to multiple CC ligands produced by ovar-
ian cancer cells, and MA, VCAM1, an adherence moledule
and ligand for VLA-4 integrin and induced on endothelial
cells by tumor necrosis factor (TNFα), interleukin 1α
(IL1α) and certain other cytokines. We also detected
increased expression of phosphorylated phospholipase
A2 (sPLA2), the activated cytosolic form of the protein
that releases arachidonic acid from membranes (a critical
early step in the eicosanoid pathway) and that can induce
CXCL8 (IL-8), IL-6, and CD44 production. Our previous
gene profile analysis of the EOC peritoneum suggested
that CXCL8 (IL-8) has a central role in these inflammatory
cell pathways [9,12]. Analysis of the mined data for both
sPLA2 (group 2a) and cPLA2 (group 4a) revealed signifi-
cant differences in transcript levels, being higher in EOC
tumor (n = 8) or peritoneum (n = 10) than in benign per-
itoneum (n = 5). These differences were statistically signif-
icant for cPLA2 and sPLA2 respectively in EOC vs benign
peritoneum (P = 0.004) and P = 0.02 and for both cPLA2
and sPLA2 in EOC tumor vs benign peritoneum (P =
0.005 for both). The P values were based on a nonpara-
metric rank-sum test for comparing samples with multiple
endpoints [14].Journal of Translational Medicine 2006, 4:30 http://www.translational-medicine.com/content/4/1/30
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Peritoneum biopsy specimens from women with benign
pelvic conditions contained fewer leukocytes (Fig. 2) than
did peritoneal specimens from patients with EOC, which
demonstrated more extensive leukocyte infiltration. Indi-
rect immunoperoxidase staining with anti-CD68 or anti-
CD3 monoclonal antibodies revealed that the leukocyte
infiltrates consisted of two main populations: MO/MA
(CD68+) and T cells (CD3+). LCA was expressed by most
peritoneal tissue leukocytes in both malignant and benign
conditions. Other cell populations, including granulo-
cytes, B cells, and NK cells, were rare (data not shown).
CD68+ (MO/MA) and CD3+ (T-cell) infiltrates were
examined in tumor-free peritoneal tissues from 19 of the
20 patients with EOC (one sample was unsuitable for
assessment). The mean number of MO/MA per 0.08 mm2
field in the EOC peritoneum was 16.8 and that of T cells
was 11.2, as compared with 6.4 MO/MA and 2.6 T cells
per field in benign peritoneum (Table 2). MO/MA were
substantially more common than were T cells (Table 2) (P
= 0.0002 by paired t-test). By contrast, the mean numbers
of B cells (CD20+) and NK cells (CD56+) were 4.5 and 1.6
per field in the EOC peritoneum respectively but were
rarely detected in benign peritoneum.
Numbers of CD68+ and CD3+ cells were also examined
in paired samples where peritoneal tissues were available
from each side of the pelvis. Paired t tests showed no sig-
nificant differences between the two sides (Table 3). This
bilateral presence of MO/MA and T-cell infiltrates in the
pelvic peritoneum suggests a spatially generalized distri-
bution pattern rather than a site-specific effect. In the 5
EOC cases in which paired superficial (submesothelial
and deeper stroma) samples were available for compari-
son, more CD3+ cells were found near the mesothelial
surface than in the deeper stroma (P = 0.020). CD68+
cells were present in large numbers at both levels.
We next examined the MO/MA population, our primary
focus for this study, at the cellular proteomic level. The
monoclonal antibodies (mAbs) used included those that
recognize CD163, CCR1, CXCL8, VCAM1 and cPLA2.
In the present experiments, we examined the two main
mononuclear cell populations, CD68+ and CD3+, by
indirect immunofluorescence costaining using confocal
microscopy, for characteristics that would help to identify
functional subsets. Because CD68+ cells were the domi-
nant population in the peritoneum, we reasoned that
CD68+ cells (or some subset of those cells) could be a
major source of the CXCL8 gene expression product in the
peritoneum.
Peritoneal biopsy specimens from 7 patients and ascites
cytopreparations from 3 patients were tested with triple-
antibody staining and evaluated by confocal microscopy.
Figure 3 (Row 1) shows surface peritoneum with positive
staining for cytokeratin, CD31 (endothelial cells), and
CD68. Marked infiltration of CD68+ cells is seen both
below and within the surface mesothelium. This is com-
pared with the peritoneum from a patient with a benign
condition where only the keratin positive surface mes-
othelium is shown along with some endothelial cells (Fig.
3, Row 2). The proportions of CD68+ and CD3+ mono-
nuclear leukocytes that coexpress products of certain
genes differentially overexpressed in the peritoneal tran-
scriptome profile (Figure 1) are shown in Table 4. Figure
3 and Table 4 show that CXCL8 (IL8), which appears to
have a central position in the peritoneal inflammatory
transcriptome, was expressed more often on CD68+ cells
than on the CD68+ CD163+ subset. CD163 has been
identified specifically on a subset of differentiated MO/
MA, and might have a role in adaptive immunity [15]. To
summarize the important observations, CCR1, the chem-
Selected genes expressed at different levels in the peritoneum and stroma of patients with EOC vs in patients with benign pel- vic disease Figure 1
Selected genes expressed at different levels in the peritoneum and stroma of patients with EOC vs in patients with benign pel-
vic disease. The red bars indicate the malignant phenotype and the blue bars the benign controls. The significance level of each 
gene expression between benign and malignant phenotypes is presented as P(t2) values.
Gene symbol p value
CD3 delta 0.472
CD3 gamma 0.068
PLA2G2A 0.002
IL8 0.022
CD163 0.013
VCAM1 0.015
CCR1 0.043
Gene symbol p value
CD3 delta 0.472
CD3 gamma 0.068
PLA2G2A 0.002
IL8 0.022
CD163 0.013
VCAM1 0.015
CCR1 0.043
Gene symbol p value
CD3 delta 0.472
CD3 gamma 0.068
PLA2G2A 0.002
IL8 0.022
CD163 0.013
VCAM1 0.015
CCR1 0.043Journal of Translational Medicine 2006, 4:30 http://www.translational-medicine.com/content/4/1/30
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okine receptor that binds to a number of different ligands
produced in the environment of EOC was expressed on
60.3% (range 44–83%) of CD68+ cells and on only
15.1% (range 0–53%) of CD3+ cells in the peritoneum.
Proportions of CCR1 expression were 80.7% and 4% on
ascitic CD68+ and CD3+ cells, respectively. The propor-
tion of CD68+ cells or CD68+ CCR1+ cells that coex-
pressed CXCL8 was also higher than in the CD3+ or CD3+
CCR1+ populations. These results suggest that peritoneal
MO/MA might be an important source of CXCL8 in the
peritoneal environment of EOC.
We found the proportion of peritoneal CD68+ cells that
coexpressed CD163 to vary from 19% to 78%; cells that
were CD68+CD163+CXCL8+ usually contributed less
than 10% of total CD68+ cells (Figure 3, rows 3&4 &
Table 4). In the EOC peritoneum, though a higher propor-
tion were present in ascites, CD68+ cells were more often
detected within the surface layer of the mesothelium than
were CD163+ cells, which seemed to be concentrated
below the mesothelial surface. However, in benign condi-
tions, CD163+ cells, though present in smaller numbers,
seemed to be more broadly distributed under the mes-
MO/MA & T-cell infiltration in peritoneum Figure 2
MO/MA & T-cell infiltration in peritoneum. Left upper shows peritoneum of patient w/benign fibrothecoma with scant 
LCA+ leukocytes below the single layer of mesothelium. Remaining 5 panels show tumor-free peritoneum from a patient with 
EOC. Upper middle shows large number of LCA+ cells; upper right shows large number of CD68+ cells; lower left shows rel-
atively fewer CD3+ cells; lower middle shows negative isotype control; lower right shows H&E. Magnification---200×
EOC Isotype Control EOC CD3 
EOC CD68 EOC LCA
Benign LCA
EOC H&E EOC Isotype Control EOC CD3 
EOC CD68 EOC LCA
Benign LCA
EOC Isotype Control EOC CD3 
EOC CD68 EOC LCA
Benign LCA
EOC H&E EOC H&E
Table 2: Median numbers of immune cells expressing CD3, CD68, and LCA in peritoneal tissue from patients with EOC or benign 
ovarian tumors
CD3 (T cells) CD68 (MO/MA) CD45 (LCA)
Left Right Average Left Right Average Left Right Average
EOC 7.4 9.5 8.7 14.7 15.3 15.3 17.4 18.2 18.1
Benign 1.7 2.0 1.7 7.2 4.1 5.3 3.7 4.7 4.1
P-value 0.012 0.016 0.002 0.038 0.002 <0.001 0.003 0.001 <0.001
Values are expressed as median absolute numbers of cells per 0.08-mm2 field.
MO/MA, monocytes/macrophages; LCA, leukocyte common antigen.Journal of Translational Medicine 2006, 4:30 http://www.translational-medicine.com/content/4/1/30
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othelium. The antibody to CD68 used here recognizes a
lysozyme marker that can sometimes be coexpressed by
keratin-positive epithelial cells [16]. Some large lymphob-
lastoid T-cells may also coexpress CD68, as suggested by
the presence of large ascitic mononuclear cells showing
surface staining for CD3 and cytoplasmic staining for the
CD68 antigen. CD3 costaining with CD68+  or with
CD163+ was rarely observed in the peritoneum, support-
ing the specificity of the antibody staining for T cells, total
MO/MA, and the CD163+ MO/MA subset. CXCL8 was
expressed on the surface epithelium in both malignant
and benign conditions (data not shown), suggesting that
CXCL8, even at low levels, may have a functional role in
the absence of cancer.
VCAM1, an important adhesion molecule, was also
expressed primarily by CD68+ cells (53%) and by CD31+
endothelial cells but only infrequently by CD3+  cells
(3.6%) (Table 4). Finally, CD68+ cells and the CD163+
subset in both peritoneal and ascitic cells also expressed
substantial amounts of pcPLA2 (Figure 4). However, the
pattern of pcPLA2 expression both in the peritoneum and
in ascitic cells seemed to differ between the total popula-
tion of CD68+ cells and the CD163+ cells; CD68+ cells
showed both cytoplasmic and nuclear staining, and
CD163+ cells showed costaining of pcPLA2 only in the
nucleus.
Conclusion
Collectively, our results represent the first steps in show-
ing that inflammatory cells have a spatially generalized
distribution pattern in the pelvic peritoneum of EOC and
that the inflammatory cell subsets are both quantitatively
and qualitatively different from the patterns typical of
benign pelvic disease. These findings complement those
of our previous study of the EOC peritoneal transcriptome
[9] and could suggest a common biologic effect. The
inflammatory cell infiltrates in cancer could contribute to
antitumor effects or, conversely, promote invasion and
metastasis. Our previous studies [17,18] suggest that
ascitic MO/MA, representing a substantial proportion of
the intraperitoneal inflammatory cell environment,
include cells that exhibit defective Fcγ R [18]mediated
activity or mediate T cell suppressor functions[17]. Here
we showed that tissue from nontumor-involved perito-
neum in patients with EOC exhibited substantial leuko-
cyte infiltrates in comparison with peritoneal tissues in
patients with benign pelvic disease and that the infiltrate
consisted mainly of MO/MA and, to a lesser extent, T cells.
Other cells (NK [CD56+] and B cells [CD20+]) were
found, but in much lower numbers. These results lead us
to speculate that MO/MA and T-cell infiltrates in the peri-
toneum were responding to a general migration stimulat-
ing effect; given their proximity to the peritoneal cavity,
the large numbers of MO/MA and T cells found in ascitic
fluid could well have originated from cells that had
migrated into the submesothelial stroma from an exten-
sive network of small capillary vessels, facilitated by
expression of adhesion molecules in the capillary
endothelium. These views are consistent with the work of
Alberto Mantovani [19,20] who has demonstrated the
effect of tumor cell products on the "polarization" of MA.
In our studies on the peritoneum, we found substantial
numbers of CD68+ cells, and CD68+ CD163+ cells, to be
concentrated near the mesothelium. The CD68+ CD163-
population in particular appeared more likely to coex-
press CXCL8, a proangiogenic chemokine that can influ-
ence the migration of different leukocyte populations. The
presence of CD68 cells within the mesothelial cell layer
also suggests that these cells are in transit to the peritoneal
cavity compartment or ascitic fluid.
A number of chemokines might contribute to the migra-
tion and activation of leukocytic as well as other cells in
the EOC environment. Migration effect is dependent
largely on the expression of complementary receptors of
ascites for a number of CC or CXC chemokines (named
for the arrangement of their first two cysteine residues). As
Table 3: The comparison of immune cells with positive CD3, CD68, and LCA markers between left and right sides in patients with 
EOC.
Marker and Location No. of Samples Average Difference (Left – 
Right)
P Value
CD3
Peritoneum 15 Median -0.33 0.89
Stroma 5 Median -2.40 0.42
CD68
Peritoneum 15 Median 0.57 0.84
Stroma 5 Median 0.10 0.97
LCA
Peritoneum 15 Median 1.27 0.77
Stroma 5 Median -4.90 0.29Journal of Translational Medicine 2006, 4:30 http://www.translational-medicine.com/content/4/1/30
Page 8 of 11
(page number not for citation purposes)
we have shown here and elsewhere [12,21], CXCL8
appears to have a prominent role in the peritoneal and
ascitic CD68+ population and specifically in CCR1+ cells.
At least nine CC chemokines, many of them associated
with EOC [21,22], can serve as ligands for CCR1. Here we
found CCR1, also highly expressed in the peritoneal
microarray profile, on substantial numbers of peritoneal
MO/MA and on some T cells, suggesting that CCR1, could
play an important role in migration of certain cell popu-
lations that express this receptor.
CXCL8 can be induced by various cytokines, including IL-
1, TNFα, IL-3, IL-13, and IL-7, most of which are produced
in EOC patients and can be induced H2O2 and hypoxia.
CXCL8 binds to CXCR1 or CXCR2, either of which can be
expressed on resting T cells but are not usually on mono-
cytes. We found CXCL8 to be produced on a large propor-
tion of MO/MA and, more variably, on CD3+ cells.
Moreover, only a very low proportion (< 10%) of the
CD68+CD163+ subset produced CXCL8. CD163 has
been linked with IL-10 release in atheromatous disease
[23], though in the pig, it has been associated with adap-
tive immunity [15]. The functional role of CD163+ MO/
MA in EOC is yet to be determined.
Triple immunofluorescence costaining of frozen right peritoneal tissues were stained with CD68 (red), CD31 (blue), and kera- tin (CK) (green) antibodies (Rows 1 & 2) Row 1, peritoneal cells from a patient with EOC (ID 266 m) appear yellow from the  colocalization of CD68 (red) and CK (green) on some surface mesothelial cells Figure 3
Triple immunofluorescence costaining of frozen right peritoneal tissues were stained with CD68 (red), CD31 (blue), and kera-
tin (CK) (green) antibodies (Rows 1 & 2) Row 1, peritoneal cells from a patient with EOC (ID 266 m) appear yellow from the 
colocalization of CD68 (red) and CK (green) on some surface mesothelial cells. CD31 staining (blue) indicates endothelial cells 
just under the mesothelium. Row 2, peritoneal cells from a patient with benign cystic teratoma of the ovary (ID 283b) show 
prominent staining for keratin in the single cell mesothelial layer but no staining for CD68 staining (red) and positive staining 
for endothelial cells (blue). Rows 3 and 4, peritoneal cells from patient ID#235 showed colocalization of CD68 (blue) and 
CD163 (green) appearing cyan color; CD68 (blue) and CXCL8 (red) costaining showed magenta effect and no color changed in 
CD163+ cells (green). Images were analyzed by confocal laser scanning microscopy (magnification 400×). H&E stained sections 
are shown for comparison.
CD68/CK CD68/CD31 CD31/CK CD68/CD31/CK
DIC 
(Overlay)
ID#283b
ID#266m
H&E
ID#235
CD68 CD163 IL8
CD68/CD163 CD163/IL8 CD68/IL8 CD68/CD163/IL8
H&EJournal of Translational Medicine 2006, 4:30 http://www.translational-medicine.com/content/4/1/30
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Elevated levels of the pro-angiogenic chemokine CXCL8
(IL8) have been detected in a variety of tumors, including
solid EOC [24] and EOC ascites fluid [25] and may pro-
mote tumor growth. Low levels have also been detected in
serum of certain normal subjects, and we have observed
that the single layer of mesothelium in benign pelvic dis-
ease may be positive for this cytokine (data not shown).
Unpublished data from the Human Cancer Immunology
Research Core Facility of M. D. Anderson Cancer Center,
moreover, indicate that 8 of 40 normal donors (all
females) had IL-8 levels higher than the lowest standard
of 9 pg/ml (Dr. James Reuben, personal communication).
These findings suggest that lower levels of CXCL8 might
have a physiologic role.
Cells that produce CXCL8 in the peritoneum of patients
with EOC might be expected to contribute to elevated lev-
els of CXCL8 in the peritoneal, ascitic, and blood com-
partments of such patients. CXCL8 is likely to have an
important role in the development or spread of EOC; it,
along with vascular endothelial growth factor, has been
linked with unfavorable prognosis in EOC [26]. The TNF-
related apoptosis-inducing ligand (TRAIL) can trigger
apoptosis in many malignant cells [27], but CXCL8 has
been shown to block TRAIL-induced cell death by convert-
ing a TRAIL-sensitive ovarian cancer cell line (OVCAR3)
into a TRAIL-resistant one. CXCL8 may also regulate the
expression of a member of the mitogen-activated protein
kinase superfamily, p38γ [28] and with VEGF contribute
to increased endothelial capillary functions. Lysophos-
phatidic acid (LPA), a phospholipid produced from
malignant ovarian epithelium, can enhance the expres-
sion of CXCL8 by tumor cells and stimulate EOC cell inva-
sion by enhancing membrane type-1 (MT1) matrix
metalloproteinase (MMP) mediated activation of MMP2
[29]. Interestingly, cPLA2, an activated enzyme involved
in liberating arachidonic acid from cell membranes and
dependent on MAPK-induced phosphorylation [30] was
highly expressed in CD68+ cells and the CD68+CD163+
subset. p42/44 and p38 MAPK activation is required prior
to translocation to the nucleus [31]. Activation of cPLA2
and other phosphorylates by cytokines in the environ-
ment of EOC may contribute to CXCL8 production. Ara-
chidonic acid is the precursor of fatty acid derivatives,
including LPA, leukotrienes, prostaglandins, thrombox-
anes, and other important components of the eicosanoid
pathways. LPA activates several biological responses
through its binding and activation of G-protein-coupled
receptors, and has been detected at elevated levels in the
ascites and serum of patients with EOC [32].
We might speculate that chemokines and certain
cytokines could be involved in recruiting MO/MA and cer-
tain T cells into the submesothelial stroma of the perito-
neum, where such cells could contribute to tissue
reorganization, tumor cell invasion, angiogenesis, capil-
lary leakage, and the production of ascites.
The cytokines most often detected in serum and ascites of
patients with EOC include TNFα, IL-10, IL-6, CSF1
Table 4: Proportions and mean proportions across samples for CD68+ and CD3+ mononuclear leukocytes expressing CCR1, IL-8, and 
VCAM1 by confocal microscopy.
ANTIBODIES PERITO NEAL SPECIM ENS ASCITES
TS-266 TS-265 TS-235 TS-236 TS-267 TS-242 TS-256 M eans ASC290 ASC288 ASC278 Means
CD68+/CCR1+ 65 51 45 44 76 58 83 60.3 87 77 78 80.7
C D 6 8 + / I L 8 + 6 13 53 83 64 56 67 4 5 0 . 75 5 5 2 4 2 4 9 . 7
CD68+/CCR1+IL8+ 66 38 28 30 46 42 37 41 45 35 48 42.7
C D 3 + / C C R 1 + 5 3 1 9 1 8 6208 1 5 . 1 0 1 0 24
CD3+/IL8+ 80 45 19 34 7 4 8 28.1 0 10 2 4
CD3+/CCR1+IL8+ 47 24 5 11 0 0 0 12.4 0 10 2 4
CD68+/CD163+ 19 38 31 43 67 39 78 45 30 36 91 52.3
CD163+/IL8+ 22 7 0 20 11 45 22 18.1 60 65 26 50.3
CD68+/CD163+IL8+ 5 3 0 9 4 22 19 8.9 15 29 32 25.3
CD68+/VCAM1+ 59 94 68 60 55 4 29 52.7 79 81 26 62
C D 6 8 + / C D 3 + 1012063 1 . 9 1 93 31 5 2 2 . 3
C D 3 + / V C A M 1 + 405400 1 2 3 . 6 3 86 93 1 4 6
C D 6 8 + / C D 3 + V C A M 1 + 1010002 0 . 6 1 63 1 9 1 8 . 7
CD3/CD68 Ratio 1 to 2 1 to 11 1 to 4 1 to 4 1 to 2 1 to 2 1 to 8 1 to 2 1 to 2 1 to 2
Disease Stage III III III III III II II III III III
Histology C E S/E S/E S S/E E S S S
S = serous; E = endometriod; C = clear cellJournal of Translational Medicine 2006, 4:30 http://www.translational-medicine.com/content/4/1/30
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(MCSF), IL-1, and TGFβ isotypes, all of which can be pro-
duced by activated MA [17,33-37] or by the tumor cells
[10,38]. TNFα and IL-1α enhance the expression of adhe-
sion molecules on endothelial cells, thereby contributing
to leukocyte attachment and migration. In our study,
VCAM1 was coexpressed on both CD31+ endothelial cells
and on MO/MA but not on most CD3+ cells, suggesting
that the CD68+ cells and CD31+ endothelial cells in par-
ticular might be under the influence of VCAM1-sensitive
cytokines released into the peritoneal microenvironment.
VCAM1 is upregulated on cytokine stimulated endothe-
lium. Such a release could be an important early step in
the migration behavior of MO/MA into the peritoneum
and ascitic fluid. The presence of endothelial cells
(CD31+) in proximity to and the CD68+ cells either inter-
spersed in or just under the mesothelium, suggest that
there is a close spatial relationship of peritoneal MO/MA
to ascitic MO/MA.
In summary, this study represents the first description of
the inflammatory cell response in the peritoneum of
patients with EOC. Our findings here support and com-
plement our previous gene profiling study of the perito-
neum [9]. We conclude that peritoneal MA that are
separated spatially from tumor cells share several similar
phenotypic characteristics and express activated gene
products that could have important roles in tumor growth
and metastases.
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